Literature DB >> 16155011

Genetics of myeloid malignancies: pathogenetic and clinical implications.

Stefan Fröhling1, Claudia Scholl, D Gary Gilliland, Ross L Levine.   

Abstract

Myeloid malignancies are clonal disorders that are characterized by acquired somatic mutation in hematopoietic progenitors. Recent advances in our understanding of the genetic basis of myeloid malignancies have provided important insights into the pathogenesis of acute myeloid leukemia (AML) and myeloproliferative diseases (MPD) and have led to the development of novel therapeutic approaches. In this review, we describe our current state of understanding of the genetic basis of AML and MPD, with a specific focus on pathogenetic and therapeutic significance. Specific examples discussed include RAS mutations, KIT mutations, FLT3 mutations, and core binding factor rearrangements in AML, and JAK2 mutations in polycythemia vera, essential thrombocytosis, and chronic idiopathic myelofibrosis.

Entities:  

Mesh:

Year:  2005        PMID: 16155011     DOI: 10.1200/JCO.2005.05.010

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  98 in total

1.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

Review 3.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

4.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

5.  Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.

Authors:  S E Langabeer; F Ni Ainle; E Conneally; M Lawler
Journal:  Ir J Med Sci       Date:  2007-04-18       Impact factor: 1.568

6.  TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.

Authors:  Xiaopeng Tian; Yang Xu; Jia Yin; Hong Tian; Suning Chen; Depei Wu; Aining Sun
Journal:  Int J Hematol       Date:  2014-05-24       Impact factor: 2.490

Review 7.  Recent advances and novel agents for FLT3 mutated acute myeloid leukemia.

Authors:  Rahul Pawar; Omar Preet Singh Bali; Bharat Kumar Malhotra; Gurpreet Lamba
Journal:  Stem Cell Investig       Date:  2014-03-20

8.  AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias.

Authors:  Stephen M Sykes; Steven W Lane; Lars Bullinger; Demetrios Kalaitzidis; Rushdia Yusuf; Borja Saez; Francesca Ferraro; Francois Mercier; Harshabad Singh; Kristina M Brumme; Sanket S Acharya; Claudia Scholl; Claudia Schöll; Zuzana Tothova; Eyal C Attar; Stefan Fröhling; Ronald A DePinho; Scott A Armstrong; D Gary Gilliland; David T Scadden
Journal:  Cell       Date:  2011-09-02       Impact factor: 41.582

9.  Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.

Authors:  K Nowek; S M Sun; L Bullinger; E M J Bindels; C Exalto; M K Dijkstra; K van Lom; H Döhner; S J Erkeland; B Löwenberg; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2015-07-15       Impact factor: 11.528

Review 10.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.